echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > ARD: EULAR/ACR 2021: Diagnosis, management and monitoring of interleukin 1-mediated autoinflammatory diseases to consider

    ARD: EULAR/ACR 2021: Diagnosis, management and monitoring of interleukin 1-mediated autoinflammatory diseases to consider

    • Last Update: 2022-08-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Background : Interleukin- 1 ( IL-1 )-mediated systemic autoinflammatory diseases, including cold porphyrin-associated periodic syndrome ( CAPS ), tumor necrosis factor receptor-associated periodic syndrome ( TRAPS ), onychomycosis Valonate Kinase Deficiency ( MKD ) and IL-1 Receptor Antagonist Deficiency (DIRA) , belong to a group of rare immune dysregulation disorders that mainly present in early childhood with multiorgan involveme.


    Background Interleukin- 1 ( IL-1 ) mediated systemic autoinflammatory diseases including cold porphyrin-associated periodic syndrome ( CAPS ), tumor necrosis factor receptor-associated periodic syndrome ( TRAPS ), Valerate kinase deficiency ( MKD ) and IL-1 receptor antagonist deficiency (DIRA) , belong to a group of rare immune dysregulation disorders that primarily present in early childhood with multiorgan involveme.


    Objective To establish evidence-based recommendations for the diagnosis, treatment, and monitoring of patients with IL-1- mediated autoinflammatory diseases to standardize their manageme.


    Methods A multinational, multidisciplinary working group of physician specialists was established, including rheumatologists, patients or caregivers, and relevant healthcare professiona.


    RESULTS : The working group designed five overarching principles, 14 statements related to diagnosis, 10 statements about treatment, and 9 focused on long-term monitoring, all of which were evidence-based and / or consensus -based IL-1- mediated Surveillance of patients with disea.


    Results The working group designed five overarching principles, 14 statements related to diagnosis, 10 statements about treatment, and 9 focused on long-term monitoring, all of which are evidence-based and / or consensus-based for IL-1- mediated disease patient monitori.


    Conclusions: The 2021 EULAR/ American College of Rheumatology Essentials represents state-of-the-art knowledge based on published data and expert opinion to guide diagnostic evaluation, treatment and monitoring of patients with CAPS , TRAPS , MKD and DIRA , and to standardize and improve care, quality of life and disease outcome.


    Source: Romano M, Arici ZS, Piskin D , et a.
    The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor -associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagoni.
    Annals of the Rheumatic Diseases2022;81:907-92 , et al Annals of the Rheumatic Diseasesleave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.